Drugs / XAF5
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01723241 | Nov 2012 → Apr 2013 | — | Topokine Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02230761 | Sep → Dec 2014 | eyelid disorder | Topokine Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01990326 | Nov 2013 → Jun 2014 | — | Topokine Therapeutics, Inc. | Suspended | No outcome recorded Stop: Business |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02607683 | Jan → Sep 2016 | eyelid disorder | Topokine Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XAF5 | “Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)” NCT02230761 ↗ |
| Known as | XOPH5 | “Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)” NCT02230761 ↗ |
| Route | Topical | “XAF5 Gel (applied to skin each night for 6 weeks)” NCT01990326 ↗ |